Wegovy (semaglutide) is an FDA-approved prescription medication for chronic weight management in adults and children 12 years and older with obesity (BMI of 30 or more) and overweight (BMI of 27 or more) with at least one weight-related condition, such as type 2 diabetes, high cholesterol, or high blood pressure
State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications
Unlike the older BMI, the BRI better distinguishes between muscle and fat, says Dr Winnett
For gut health, which is stressed by both keto and semaglutide, a quality probiotic is worth including
Each medication is developed with its own titration schedule designed to optimise patient safety and treatment outcomes
As a result, symptomatic hypotension can occur, especially in patients with reduced renal function ( TABLE 2 ), elderly patients, patients taking diuretics or medications that interfere with the renin-angiotensin-aldosterone system (RAAS), and patients with low SBP